Topic: FDA Approval of investigation drug triphendiol
Came across this and thought some might be interested
Jan 08, 2009 (M2 EQUITYBITES via COMTEX) -- MSHL | Quote | Chart | News | PowerRating -- Marshall Edwards Inc (NasdaqGM:MSHL), a specialist oncology company focused on the clinical development of novel anti-cancer therapeutics, said on 7 January that the company has received Investigative New Drug (IND) approval from the United States Food and Drug Administration (FDA) to undertake clinical studies with triphendiol as a chemosensitising agent in combination with gemcitabine.
The company stated that the approval will allow a Phase Ib study of triphendiol in combination with gemcitabine in patients with unresectable, locally advanced or metastatic pancreatic and bile duct cancers. A Triphendiol (NV-196) is an investigational drug, currently being developed as an orally-delivered chemosensitising agent, intended for use in conjunction with standard chemotoxic anti-cancer drugs for the treatment of late stage pancreatic cancer, cholangiocarcinoma and melanoma.